Suppr超能文献

孟加拉国作为一个中低收入国家,推荐并规划针对 2019 年冠状病毒病大流行的大规模疫苗接种。

Recommendation and Roadmap of Mass Vaccination against Coronavirus Disease 2019 Pandemic in Bangladesh as a Lower-Middle-Income Country.

机构信息

Department of Pharmacy, State University of Bangladesh, 77 Satmasjid Road Dhanmondi, Dhaka-1205, Bangladesh.

Department of Clinical Pharmacy and Pharmacology, Faculty of Pharmacy, University of Dhaka, Dhaka-1000, Bangladesh.

出版信息

Arch Razi Inst. 2021 Dec 30;76(6):1823-1830. doi: 10.22092/ari.2021.356357.1824. eCollection 2021 Dec.

Abstract

Low-income countries (LICs) and lower-middle-income countries (LMICs) are still deprived of the optimum doses of coronavirus disease 2019 (COVID-19) vaccines for their population, equal access and distribution, as well as mass immunization roadmaps to be implemented for achieving herd immunity and protection from the ongoing pandemic. In this short report, we are interacting with the world public health experts, as well as national and global leaders for warranting the mass vaccination drive to be more progressive against COVID-19 with equitable access of vaccines to LICs or LMICs to save the lives of the poorest country people and refugees. From several scientific databases, such as Google Scholar, PubMed, as well as national and international news websites, the data were collected data by utilizing appropriate keywords regarding the topic. Bangladesh might be exemplified in this brief communication as the representative of LMIC. As of October 14, 2021, 48% of the world's people have received at least one dose of the COVID-19 vaccine. In contrast, only 2.5% of people from LICs have come in under COVID-19 vaccination for at least a single shot. Both LICs and LMICs need far more vision and ambition, including political, administrative, and diplomatic progress along with enhancing the vaccination drive for their population to be immunized through simultaneous mass vaccination progress of other countries with implementing public health safety measures against the COVID-19 pandemic.

摘要

低收入国家(LICs)和中低收入国家(LMICs)仍然缺乏为其人口提供最佳剂量的 2019 年冠状病毒病(COVID-19)疫苗,无法平等获得和分配疫苗,也无法实施大规模免疫计划,以实现群体免疫并防止当前大流行。在这份简短的报告中,我们正在与世界公共卫生专家以及国家和全球领导人互动,以确保大规模疫苗接种运动更具针对性,确保向 LICs 或 LMICs 公平提供疫苗,以拯救最贫穷国家人民和难民的生命。我们从 Google Scholar、PubMed 等多个科学数据库以及国家和国际新闻网站收集了相关数据,并利用了与主题相关的适当关键词。孟加拉国可能是 LMIC 的代表。截至 2021 年 10 月 14 日,全球已有 48%的人口至少接种了一剂 COVID-19 疫苗。相比之下,只有 2.5%的 LICs 人口至少接种了一剂 COVID-19 疫苗。LICs 和 LMICs 都需要更远大的眼光和雄心壮志,包括在政治、行政和外交方面取得进展,同时加强疫苗接种运动,使本国人民通过其他国家同步进行大规模疫苗接种并实施针对 COVID-19 大流行的公共卫生安全措施来实现免疫。

相似文献

1
Recommendation and Roadmap of Mass Vaccination against Coronavirus Disease 2019 Pandemic in Bangladesh as a Lower-Middle-Income Country.
Arch Razi Inst. 2021 Dec 30;76(6):1823-1830. doi: 10.22092/ari.2021.356357.1824. eCollection 2021 Dec.
2
COVID-19 vaccination in low and middle-income countries: Creating a sustainable roadmap for promoting public health intervention.
Int J Health Plann Manage. 2024 Sep;39(5):1612-1625. doi: 10.1002/hpm.3834. Epub 2024 Aug 1.
3
COVID-19 Vaccination in Lower-Middle Income Countries: National Stakeholder Views on Challenges, Barriers, and Potential Solutions.
Front Public Health. 2021 Aug 6;9:709127. doi: 10.3389/fpubh.2021.709127. eCollection 2021.
4
The COVID-19 vaccination experience in Bangladesh: Findings from a cross-sectional study.
Int J Immunopathol Pharmacol. 2021 Jan-Dec;35:20587384211065628. doi: 10.1177/20587384211065628.
5
Urgent call for mass immunization against coronavirus in Bangladesh.
Sci Prog. 2021 Oct;104(4):368504211058562. doi: 10.1177/00368504211058562.
6
COVID-19 Vaccines: How Efficient and Equitable Was the Initial Vaccination Process?
Vaccines (Basel). 2022 Dec 20;11(1):11. doi: 10.3390/vaccines11010011.
8
Research priorities to reduce the impact of COVID-19 in low- and middle-income countries.
J Glob Health. 2022 Apr 15;12:09003. doi: 10.7189/jogh.12.09003. eCollection 2022.
9
COVID-19 Vaccine Diplomacy and Equitable Access to Vaccines Amid Ongoing Pandemic.
Arch Med Res. 2021 Oct;52(7):761-763. doi: 10.1016/j.arcmed.2021.04.006. Epub 2021 Apr 23.
10
The impact of delayed access to COVID-19 vaccines in low- and lower-middle-income countries.
Front Public Health. 2023 Jan 12;10:1087138. doi: 10.3389/fpubh.2022.1087138. eCollection 2022.

引用本文的文献

3
Status of psychological health of students following the extended university closure in Bangladesh: Results from a web-based cross-sectional study.
PLOS Glob Public Health. 2022 Mar 31;2(3):e0000315. doi: 10.1371/journal.pgph.0000315. eCollection 2022.
4
Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies.
J Infect Public Health. 2023 Jan;16(1):4-14. doi: 10.1016/j.jiph.2022.11.024. Epub 2022 Nov 19.
5
Characteristics of the SARS-CoV-2 Omicron (B.1.1.529) Variant and Emerging Impact on Global Public Health.
Clin Pathol. 2022 Sep 20;15:2632010X221124908. doi: 10.1177/2632010X221124908. eCollection 2022 Jan-Dec.
6
The Upsurge of Diarrhea Amid COVID-19 Pandemic Makes Matter Worse in Bangladesh: A Call to Action.
Gerontol Geriatr Med. 2022 Aug 8;8:23337214221117419. doi: 10.1177/23337214221117419. eCollection 2022 Jan-Dec.
7
Comparative evaluation of authorized drugs for treating Covid-19 patients.
Health Sci Rep. 2022 Jun 13;5(4):e671. doi: 10.1002/hsr2.671. eCollection 2022 Jul.
8
Indiscriminate Use of Antibiotics for COVID-19 Treatment in South Asian Countries is a Threat for Future Pandemics Due to Antibiotic Resistance.
Clin Pathol. 2022 May 18;15:2632010X221099889. doi: 10.1177/2632010X221099889. eCollection 2022 Jan-Dec.
9
The SARS-CoV-2 Omicron (B.1.1.529) variant and the re-emergence of COVID-19 in Europe: An alarm for Bangladesh.
Health Sci Rep. 2022 Mar 13;5(2):e545. doi: 10.1002/hsr2.545. eCollection 2022 Mar.

本文引用的文献

1
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK.
Nat Med. 2021 Dec;27(12):2127-2135. doi: 10.1038/s41591-021-01548-7. Epub 2021 Oct 14.
2
Urgent call for actionable measures to fight the current co-epidemic of dengue burden during the SARS-CoV-2 delta variant era in South-Asia.
Ethics Med Public Health. 2021 Dec;19:100726. doi: 10.1016/j.jemep.2021.100726. Epub 2021 Oct 2.
3
4
Impact of SARS-CoV-2 delta variant (B.1.617.2) in surging second wave of COVID-19 and efficacy of vaccines in tackling the ongoing pandemic.
Hum Vaccin Immunother. 2021 Nov 2;17(11):4126-4127. doi: 10.1080/21645515.2021.1963601. Epub 2021 Sep 2.
5
An overview of SARS-COV-2 epidemiology, mutant variants, vaccines, and management strategies.
J Infect Public Health. 2021 Oct;14(10):1299-1312. doi: 10.1016/j.jiph.2021.08.014. Epub 2021 Aug 16.
6
Vaccines and variants: Modelling insights into emerging issues in COVID-19 epidemiology.
Paediatr Respir Rev. 2021 Sep;39:32-39. doi: 10.1016/j.prrv.2021.07.002. Epub 2021 Jul 21.
7
COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies.
Biomolecules. 2021 Jul 6;11(7):993. doi: 10.3390/biom11070993.
8
COVID-19 Infection: Targeting Possibilities for Treatment.
Crit Rev Ther Drug Carrier Syst. 2021;38(3):75-115. doi: 10.1615/CritRevTherDrugCarrierSyst.2021035392.
10
Acceptance of a vaccine against COVID-19 - a systematic review of surveys conducted worldwide.
Bratisl Lek Listy. 2021;122(8):538-547. doi: 10.4149/BLL_2021_086.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验